06/24/2026
A drug that arose from discoveries at UT Southwestern is reaching more patients. The FDA has expanded approval of belzutifan for some earlier stage kidney cancers when used with an immunotherapy drug, marking another important step from basic research to patient care. Read more about the science behind this breakthrough and its potential impact on kidney cancer care.
Belzutifan, a first-in-class drug that arose from scientific discoveries at UT Southwestern Medical Center, has been approved by the Food and Drug Administration to treat some patients with earlier stage kidney cancers in combination with an immunothera...